TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

  • STATUS
    Recruiting
  • End date
    Dec 1, 2024
  • participants needed
    96
  • sponsor
    Taiho Oncology, Inc.
Updated on 1 May 2022

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations.

Description

Study TAS-117-201 is an open-label, single-arm Phase 2 study evaluating the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of TAS-117 in patients with advanced or metastatic solid tumors harboring germline PTEN inactivating mutations. The study will be conducted in two parts:

  • Part A: Safety lead-in (Dose Escalation and Dose Regimen Confirmation)
  • Part B: Single-arm Phase 2 study

Patients will receive TAS-117 orally every day or intermittently on a 21-day cycle

  • Part A (Dose Escalation): up to 36 adult patients with advanced or metastatic solid tumors (excluding primary brain tumors) irrespective of gene alterations. The Dose Escalation consists of 2 cohorts: Daily Dose Regimen and Intermittent Dose Regimen.
  • Part A (Dose Regimen Confirmation): approximately 6 adult or adolescent patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations
  • Part B (Phase 2): approximately 54 adult or adolescent patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations

Treatment will continue until disease progression, unacceptable toxicity, or any other of the criteria for treatment discontinuation is met. For patients who discontinue treatment for reasons other than disease progression, tumor assessments should be continued until radiologic disease progression is documented or until initiation of subsequent new anticancer therapy (whichever occurs first).

Patients will be followed for survival every 12 weeks (±2 weeks) until survival events (deaths) have been reported for 75% of enrolled patients or the study is terminated early by the Sponsor.

Details
Condition Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
Treatment TAS-117
Clinical Study IdentifierNCT04770246
SponsorTaiho Oncology, Inc.
Last Modified on1 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Dose Escalation in Part A
Histologically or cytologically confirmed advanced or metastatic solid tumors
≥18 years of age
Has progressed after standard treatment for advanced or metastatic disease or was intolerant to or ineligible for available standard therapies
Patients with solid tumors irrespective of gene alterations
Patients with at least one measurable or non-measurable lesion per RECIST1.1
Dose and Regimen Confirmation in Part A and Phase 2 (Part B)
Histologically confirmed advanced or metastatic solid tumors
Has progressed after standard treatment for advanced or metastatic disease or was intolerant or ineligible to available standard therapies
≥12 years of age. Patients age ≥12 and <18 years must have a body weight of ≥40 kg
Patients with locally confirmed germline PTEN inactivating mutations determined from a blood sample
Patients with at least one measurable lesion per RECIST 1.1

Exclusion Criteria

History or current evidence of interstitial lung disease that requires steroid medication
Current evidence of diabetes mellitus that requires insulin therapy
Prior treatment with PI3K/AKT/mTOR pathway inhibitors
Patients with primary brain tumor
Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastasis
Currently receiving chronic corticosteroid therapy of ≥10 mg/day of prednisone or its equivalent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note